Methods of promoting neurite outgrowth with soluble TAJ polypeptides
View Patent ↗The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.
1. A method of increasing neurite outgrowth, in a CNS neuron, the method comprising contacting the CNS neuron with an effective amount of an agent that reduces TAJ signaling in the neuron, wherein the agent is a soluble TAJ polypeptide, which consists of a polypeptide wherein the N-terminus is between amino acids 20-50 of SEQ ID NO:2 and the C-terminus is between amino acids 130-176 of SEQ ID NO:2.
2. The method of claim 1 , wherein the CNS neuron is a human CNS neuron.
3. The method of claim 2 , wherein the human CNS neuron is selected from the group consisting of: a CG neuron, a DRG neuron.
4. The method of claim 1 , wherein the CNS neuron is in a mammal.
5. The method of claim 4 , wherein the CNS neuron is in a human.
6. A method of promoting CNS neurite outgrowth in a subject, the method comprising: identifying a subject in need of increased neurite outgrowth, and administering to the subject an agent that decreases TAJ signaling or complex formation in a CNS neuron of the subject in an amount sufficient to increase neurite outgrowth, wherein the agent is a soluble TAJ polypeptide which consists of a polypeptide wherein the N-terminus is between amino acids 20-50 of SEQ ID NO:2 and the C-terminus is between amino acids 130-176 of SEQ ID NO:2.
7. The method of claim 6 , wherein the method further includes evaluating the subject for neuronal function.
8. The method of claim 6 , wherein the subject is a human.
9. The method of claim 8 , wherein the subject has a CNS neurodegenerative condition.
10. The method of claim 9 , wherein the neurodegenerative condition is multiple sclerosis, progressive multifocal leukoencephalopathy (PML), central pontine myelinolysis (CPM), leukodystrophies ALS, Huntington's disease, Alzheimer's disease, Parkinson's disease, or diabetic neuropathy.
11. The method of claim 6 , wherein the agent is administered in combination with a second therapeutic agent.
12. The method of claim 11 , wherein the second therapeutic agent is an analgesic, an antibiotic or a corticosteroid.
13. A method of increasing neurite outgrowth in a CNS neuron, the method comprising contacting the CNS neuron with an effective amount of an agent that reduces TAJ signaling in the neuron, wherein the agent is a soluble TAJ polypeptide fused to a heterologous amino acid sequence, wherein the N-terminus of the TAJ polypeptide is between amino acids 20-50 of SEQ ID NO:2 and the C-terminus is between amino acids 130-176 of SEQ ID NO:2.
14. The method of claim 13 , wherein the heterologous amino acid sequence comprises an Fc region of an immunoglobulin.
15. A method of promoting CNS neurite outgrowth in a subject, the method comprising: identifying a subject in need of increased neurite outgrowth, and administering to the subject an agent that decreases TAJ signaling or complex formation in a CNS neuron of the subject in an amount sufficient to increase neurite outgrowth, wherein the agent is a soluble TAJ polypeptide fused to a heterologous amino acid sequence, wherein the N-terminus of the TAJ polypeptide is between amino acids 20-50 of SEQ ID NO:2 and the C-terminus is between amino acids 130-176 of SEQ ID NO:2.
16. The method of claim 15 , wherein the heterologous amino acid sequence comprises an Fc region of an immunoglobulin.